Epilepsy expands the phenotype of L‐arginine:glycine amidinotransferase deficiency
Epilepsia · 2025
DOI: 10.1111/epi.18565 ↗Kurz gefasst
Fallbericht in der Zeitschrift Epilepsia, 2025. Verfasst von Alessandro Ferretti und 22 weiteren Autor:innen. Beteiligte Einrichtung: Pediatrics Unit, Neuroscience, Mental Health, and Sensory Organs Department, Faculty of Medicine and Psychology, Sant'Andrea University Hospital, Sap…. Hauptthemen laut MEDLINE: Amidinotransferases, Amino Acid Metabolism, Inborn Errors, Epilepsy. Die Arbeit nennt 48 Literaturangaben. Gefördert von: Italian Ministry of Health, Ministero della Salute.
Abstract (Originalsprache)
Objective
L‐arginine:glycine amidinotransferase (AGAT) deficiency is a rare autosomal recessive disorder affecting creatine biosynthesis, leading to developmental delay, intellectual disabilities, and myopathy. Unlike other creatine deficiency disorders, its link to epilepsy remains uncertain. This study presents the first reported epilepsy cases in AGAT deficiency, analyzing seizure patterns and response to creatine monohydrate supplementation.
Methods
We retrospectively analyzed two AGAT‐deficient probands identified through a national collaboration. Biochemical assessments of creatine and guanidinoacetate (GAA) levels in plasma and urine were performed using electrospray ionization tandem mass spectrometry and high‐performance liquid chromatography methods. Brain magnetic resonance spectroscopy was conducted to evaluate cerebral creatine levels pre‐ and postsupplementation.
Results
Both probands carried the homozygous c.446G>A, p.(Trp149Ter) mutation in GATM , classified as pathogenic. The first, diagnosed at birth and treated with creatine from 4 months, had normal psychomotor development but developed focal epilepsy at 6 years, controlled with carbamazepine. The second, diagnosed at 5 years, presented with psychomotor delay, behavioral disturbances, and nocturnal seizures with unknown origin from age 4 years, later developing focal tonic seizures while awake. Initially the proband was unresponsive to carbamazepine; seizure control was achieved with valproate and lacosamide. Definitive conclusions on the role of creatine supplementation in epilepsy associated with AGAT deficiency cannot be drawn, as it was not modified after seizure onset in the first proband and introduced only after seizure control in the second. Significance This study presents the first cases of epilepsy in AGAT deficiency, suggesting its prevalence may be underestimated. AGAT‐related epilepsy appears to be part of the associated developmental encephalopathy, with focal seizures and minimal impact on psychomotor development. In AGAT deficiency, epilepsy is not linked to GAA accumulation as in other creatine deficiency disorders but rather to low brain creatine levels, which may affect γ‐aminobutyric acidergic neurotransmission and seizure thresholds. The role of creatine supplementation in seizure control warrants further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatrics Unit, Neuroscience, Mental Health, and Sensory Organs Department, Faculty of Medicine and Psychology, Sant'Andrea University Hospital, Sapienza University of Rome, Rome, Italy.
- Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
- Department of Developmental Neuroscience, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Stella Maris Foundation, Pisa, Italy.
- Neuroradiology Unit, Neuroscience, Mental Health, and Sensory Organs Department, Faculty of Medicine and Psychology, Sant'Andrea University Hospital, Sapienza University of Rome, Rome, Italy.
- Laboratory of Medical Genetics, Translational Cytogenomics Research Unit, Bambino Gesù Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
- Anesthesia, Intensive Care, and Pain Medicine Unit, Department of Medical-Surgical Sciences and Translational Medicine, Sant'Andrea University Hospital, Sapienza University of Rome, Rome, Italy.
ORCID-Profile: Alessandro Ferretti, Giovanni Di Nardo, Pasquale Parisi
Förderung
- Italian Ministry of Health
- Ministero della Salute
Zitieren
APA
Ferretti, A., Battini, R., Gagliardo, O., Verrigni, D., Manca, M. B., Ferrari, A. R., Salerno, G., Boccia, R., Polese, D., Cocco, C., Zampogna, S., Di Nardo, G., Evangelisti, M., Pagani, J., Bruni, O., Romano, A., Piastra, M., Simmaco, M., Rocco, M., …, & Parisi, P. (2025). Epilepsy expands the phenotype of L‐arginine:glycine amidinotransferase deficiency. Epilepsia. https://doi.org/10.1111/epi.18565
Vancouver
Ferretti A, Battini R, Gagliardo O, Verrigni D, Manca MB, Ferrari AR, et al. Epilepsy expands the phenotype of L‐arginine:glycine amidinotransferase deficiency. Epilepsia. 2025. doi:10.1111/epi.18565
BibTeX
@article{Ferretti2025,
author = {Ferretti, Alessandro and Battini, Roberta and Gagliardo, Olga and Verrigni, Daniela and Manca, Maria Beatrice and Ferrari, Anna Rita and Salerno, Gerardo and Boccia, Rosanna and Polese, Daniela and Cocco, Chiara and Zampogna, Stefania and Di Nardo, Giovanni and Evangelisti, Melania and Pagani, Jacopo and Bruni, Oliviero and Romano, Andrea and Piastra, Marco and Simmaco, Maurizio and Rocco, Monica and Novelli, Antonio and Carducci, Claudia and Bozzao, Alessandro and Parisi, Pasquale},
title = {Epilepsy expands the phenotype of L‐arginine:glycine amidinotransferase deficiency},
journal = {Epilepsia},
year = {2025},
doi = {10.1111/epi.18565}
}
EUVIMED